The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics,
pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that
harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where
cohorts of patients will receive ascending oral doses of AG-120 to determine maximum
tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study
is a dose expansion phase where four cohorts of patients will receive AG-120 to further
evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose.
Anticipated time on study treatment is until disease progression or unacceptable toxicity